Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACZ885 PK/PD in Rheumatoid Arthritis
NCT00505089Phase 2Terminated
- Sponsor
- Novartis
- Start
- Aug 2007
- Primary completion
- May 2009
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of canakinumab in rheumatoid arthritis (RA), sponsored by Novartis. Started Aug 2007; status: terminated.
02
Drugs
canakinumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00505089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00505089.